PIL filed against Ranbaxy’s directors alleging sales of adulterated drugs

06 Jun 2013 Evaluate

In yet another trouble for the pharmaceuticals major Ranbaxy Laboratories, a public interest Litigation (PIL) appeal has been filed in the Supreme Court against the company’s directors for allegedly manufacturing and selling adulterated drugs. Manohar Lal Sharma, the petitioner, has also sought sealing of the company’s manufacturing facilities at Paonta Sahib and Devas in Madhya Pradesh, besides mentioning the Central Bureau of Investigation (CBI) as one of the respondents in the case. 

The PIL comes in the wake of the Indian pharma major being fined $500 million by the U.S. Food and Drug Administration (USFDA) for making and selling 'adulterated' drugs

Further, Sharma has also sought action against the drug regulator, Central Drug Standards Control Organization for permitting Ranbaxy to sell drugs in India, especially after the findings of the US FDA against the company. The petition which mentioned before a bench of judges Gyan Sudha Misra and Madan B Lokur would be heard next week.

Peers
Company Name CMP
Sun Pharma Inds. 1783.25
Dr. Reddys Lab 1274.40
Cipla 1502.65
Zydus Lifesciences 920.80
Lupin 2083.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×